Dendritic cell-based vaccine therapy against malignant brain tumor

Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase II clinical trial - Immunotherapy against malignant brain tumor

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTc040190103

Enrollment

Registered

2020-01-07

Start date

2013-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant gliomas

Interventions

Collaborative treatment of standard chemoradiotherapywith activated dendritic cell-based vaccine to highgrade g lioma patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histolog ical diagnosis of high-grade glioma (WHO Gr3-4) 2. Standard chemoradiation treatment is supposed to be given after surgery 3. 20< age<80 4. Performance status 0-2 5. Measurable lesions by imaging diagnosis 6. HLA-g enotyping : HLA-A2 or A24 7. No severe organ dysfunction 8. Tolerable and eligible to apheresis performance 9. No severe hemostatic disorders 10. Informed consents obtained 11. Expecting survival with more than 6 months 12. Over 4-week interval after the previous treatment

Exclusion criteria

Exclusion criteria: 1. Within 28 days after the last cancer treatment 2. Severe systemic infection, hemostatic dysfunction and organ disorders 3. Steroid treatment except used for cerebral decompression 4. Pregnant women 5. Hypersensitivity to dendritic cell vaccines 6. Severe immunolog ical disorders (autoimmune disease, immunosuppression) 7. Multiple cancers 8. Anaphylaxis to synthetic peptides

Design outcomes

Primary

Measure	Time frame
Relapse-free survival time	—

Secondary

Measure	Time frame
1. Relapse-free survival rate at 6 months 2. Overall survival time 3. Immunolog ical activity after vaccine therapy 4. Anti-tumor activity	—

Countries

Japan

Contacts

Public ContactKatsunori Goto

Shizuoka Cancer Center

scchr34@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026